• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

European Medicines Agency: leave the UK but remain the same.

作者信息

Garattini Livio, Curto Alessandro

机构信息

IRCCS Institute for Pharmacological Research Mario Negri, Ranica 24020, Italy

IRCCS Institute for Pharmacological Research Mario Negri, Ranica 24020, Italy.

出版信息

J R Soc Med. 2016 Sep;109(9):324-5. doi: 10.1177/0141076816663559.

DOI:10.1177/0141076816663559
PMID:27609795
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5017522/
Abstract
摘要

相似文献

1
European Medicines Agency: leave the UK but remain the same.欧洲药品管理局：离开英国但保持不变。
J R Soc Med. 2016 Sep;109(9):324-5. doi: 10.1177/0141076816663559.
2
Drug approval and research assessment: arguments for reform.药物审批与研究评估：改革的论据
J R Soc Med. 2016 Sep;109(9):323. doi: 10.1177/0141076816666996. Epub 2016 Aug 17.
3
Rationing new medicines in the UK.英国新药品的配给
BMJ. 2009 Jan 22;338:a3182. doi: 10.1136/bmj.a3182.
4
European Medicines Agency Perspective on Oncology Study Design for Marketing Authorization and Beyond.欧洲药品管理局对用于上市许可及后续阶段的肿瘤学研究设计的观点
Clin Pharmacol Ther. 2017 May;101(5):577-579. doi: 10.1002/cpt.612. Epub 2017 Apr 4.
5
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.从欧洲药品管理局到奥比斯项目：英国脱欧后促进肿瘤药物批准的新活动和挑战。
Lancet Oncol. 2023 Apr;24(4):e150-e160. doi: 10.1016/S1470-2045(22)00701-X.
6
For the European Medicines Agency, a decade of challenges.对于欧洲药品管理局来说，这是充满挑战的十年。
J Natl Cancer Inst. 2005 Oct 5;97(19):1403-5. doi: 10.1093/jnci/dji355.
7
European Medicines Agency pledges to publish clinical reports.欧洲药品管理局承诺发布临床报告。
BMJ. 2014 Oct 7;349:g6086. doi: 10.1136/bmj.g6086.
8
Comparing patient access to pharmaceuticals in the UK and US.比较英国和美国患者获取药品的情况。
Appl Health Econ Health Policy. 2006;5(3):177-87. doi: 10.2165/00148365-200605030-00004.
9
Medicines to remain with European Commission health directorate.药品将留在欧盟委员会卫生司。
BMJ. 2014 Oct 29;349:g6514. doi: 10.1136/bmj.g6514.
10
Regulatory watch: Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective.监管观察：中枢神经系统疾病药物研发面临的挑战：欧洲药品管理局视角
Nat Rev Drug Discov. 2016 Nov 29;15(12):813-814. doi: 10.1038/nrd.2016.237.

引用本文的文献

1
Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?欧洲的药品支出控制：是时候从定价转向预算了吗？
J R Soc Med. 2020 Mar;113(3):93-97. doi: 10.1177/0141076819894681. Epub 2019 Dec 20.
2
Health technology assessment for pharmaceutical regulation in the European Union: do we need another body?欧盟药品监管中的卫生技术评估：我们是否需要另一个机构？
J R Soc Med. 2020 Jan;113(1):12-15. doi: 10.1177/0141076819888618. Epub 2019 Nov 15.
3
HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?欧洲药品的卫生技术评估：会雷声大雨点小吗？
Eur J Health Econ. 2020 Feb;21(1):1-5. doi: 10.1007/s10198-019-01103-9.
4
Pharmaceutical pricing conundrum: time to get rid of it?药品定价难题：是时候解决它了吗？
Eur J Health Econ. 2018 Nov;19(8):1035-1038. doi: 10.1007/s10198-018-0995-x.
5
Competition in pharmaceuticals: more product- than price-oriented?制药行业的竞争：更多以产品而非价格为导向？
Eur J Health Econ. 2018 Jan;19(1):1-4. doi: 10.1007/s10198-017-0932-4.
6
Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?荷兰经济评估指南：理论上“从好到更好”，但在实践中与药品的距离却更远了？
J R Soc Med. 2017 Mar;110(3):98-103. doi: 10.1177/0141076817690395. Epub 2017 Jan 24.
7
Market approval for drugs in the EU: time to change direction?欧盟药品的市场批准：是时候改变方向了吗？
Eur J Health Econ. 2017 Nov;18(8):933-936. doi: 10.1007/s10198-016-0863-5.
8
Drug approval and research assessment: arguments for reform.药物审批与研究评估：改革的论据
J R Soc Med. 2016 Sep;109(9):323. doi: 10.1177/0141076816666996. Epub 2016 Aug 17.

本文引用的文献

1
The European Medicines Agency is still too close to industry.欧洲药品管理局与制药行业关系仍过于紧密。
BMJ. 2016 May 6;353:i2412. doi: 10.1136/bmj.i2412.
2
Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?
Pharmacoeconomics. 2016 May;34(5):423-6. doi: 10.1007/s40273-015-0377-5.
3
From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients.从适应性许可到适应性途径：采用灵活的全生命周期方法将新药带给患者。
Clin Pharmacol Ther. 2015 Mar;97(3):234-46. doi: 10.1002/cpt.59. Epub 2015 Feb 4.
4
Could co-payments on drugs help to make EU health care systems less open to political influence?药品的自付费用能否有助于使欧盟的医疗保健系统减少受到政治影响？
Eur J Health Econ. 2013 Oct;14(5):709-13. doi: 10.1007/s10198-012-0428-1.
5
Designing "Real-World" trials to meet the needs of health policy makers at marketing authorization.设计“真实世界”试验以满足药品上市许可时卫生政策制定者的需求。
J Clin Epidemiol. 2011 Jul;64(7):711-7. doi: 10.1016/j.jclinepi.2010.12.010. Epub 2011 Mar 31.
6
Modeling in pharmacoeconomic studies: funding sources and outcomes.药物经济学研究中的模型构建：资金来源与结果。
Int J Technol Assess Health Care. 2010 Jul;26(3):330-3. doi: 10.1017/S0266462310000322.
7
Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis.七个欧洲国家专利期内药品的定价与报销：一项比较分析
Health Policy. 2007 Aug;82(3):330-9. doi: 10.1016/j.healthpol.2006.11.004. Epub 2006 Nov 27.